Navigation Links
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.

BETHESDA, Md. and BRIDGEWATER, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Today, the Foundation for the National Institutes of Health and sanofi-aventis announced an unprecedented donation by the global pharmaceutical leader providing approximately $1.3 million in pharmaceutical therapies for ongoing use in clinical trials and other therapeutic treatments at the National Institutes of Health (NIH) Clinical Center.

Designated by the Foundation for NIH as the Clinical Center Drug Donation Project, this gift has been provided by sanofi-aventis U.S. to be used for scientific purposes as defined and overseen by the NIH. The donation of three drugs - docetaxel (Taxotere(R)), oxaliplatin injection (Eloxatin(R)) and enoxaparin sodium injection (Lovenox(R)) - will be made over the course of one year.

"At a time when the costs of managing clinical trials are on the rise and budgets are extremely tight, receiving pharmaceutical products at no cost enables us to extend the Center's resources to continue its groundbreaking research in many promising areas such as cell processing, imaging sciences and critical care," said Charles M. Sanders, M.D., chairman of the Foundation for NIH. "We are grateful to sanofi-aventis for advancing NIH-sponsored clinical research with this generous donation and hope that other pharmaceutical companies will follow its lead."

"We are proud to support the ability of the NIH to pursue new and cutting-edge research by freeing up much needed resources," said Marc Cluzel, M.D. Senior Vice President Research & Development at sanofi-aventis. "We have been committed to supporting clinical research in key therapeutic areas for more than 50 years, and this partnership is another example of the company's steadfast commitment to advancing research, and ultimately, helping patients."

The NIH Clinical Center is the largest hospital in the United States entirely devoted to clinical research, with more than 1,500 studies currently in progress, most of which are clinical trials. These clinical trials play a crucial role in evaluating potential therapeutic treatments for many critical health challenges facing the U.S. and the rest of the world. Since the Clinical Center's opening in 1953, more than 350,000 patients from all 50 states and around the world have participated in its clinical research.

About the Foundation for the National Institutes of Health

The Foundation for the National Institutes of Health was established by the United States Congress to support the mission of the National Institutes of Health - improving health through scientific discovery. The Foundation identifies and develops opportunities for innovative public-private partnerships and collaborations and brings together industry, academia, and the philanthropic community in support of the efforts of the NIH. As a non-profit, 501(c)(3) corporation, the Foundation raises private-sector funds for a broad portfolio of unique programs that complement and enhance NIH priorities and activities. The Foundation's Web site address is

The NIH - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments and cures for common and rare diseases. For more information about NIH and its programs, visit

About sanofi-aventis

Sanofi-aventis is a leading global pharmaceutical company that discovers, develops and distributes therapeutic solutions to help improve the lives of patients. Sanofi-aventis is listed in Paris (Euronext: SAN) and in New York (NYSE: SNY). For more information, visit: or .

Please see the accompanying Eloxatin (oxaliplatin injection), Lovenox (enoxaparin sodium injection), and Taxotere (docetaxel) Injection Concentrate full prescribing information, including Boxed Warnings.

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include product development, product potential projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans" and similar expressions. Although sanofi-aventis' management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in sanofi-aventis' annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements.

    Noelle Boyd        Richard M. Scarfo
    Sanofi-aventis     Foundation for the National Institutes of Health
    (908) 981-6489     (301) 496-9921

SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. GeneGo and the Cystic Fibrosis Foundation Collaborate to Advance Understanding of Cystic Fibrosis
2. More Than 230 Cyclists to Ride in Amgen California Coast Classic Bike Tour to Raise $1.3 Million for Arthritis Foundation
3. International Atomic Energy Agency and National Foundation for Cancer Research Launch Major Initiative to Improve Cancer Prevention and Treatments in Developing Countries
4. Melanoma Research Foundation and Seattle Cancer Care Alliance Host Educational Symposium and Reception for Melanoma Patients, Family Members and Healthcare Providers
5. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
6. The Parkinsons Disease Foundation Commemorates its 50th Anniversary with Special Scientific Symposium on Parkinsons Disease
7. Rutgers physicist earns prestigious Packard Foundation Science and Engineering Fellowship
8. Agendia BV Announces That its Chief Research Officer Laura van t Veer has Received a 2007 Breast Cancer Research Foundation Award
9. John Timberlake, Valeritas Executive Vice President and General Manager, Named Executive of the Year by the Diabetes Foundation
10. Genasense(R) Triple Combination Therapy in Advanced Melanoma Presented at Chemotherapy Foundation Symposium
11. eHealth Initiative Foundation Launches Collaborative Research Effort to Improve Drug Safety
Post Your Comments:
(Date:11/24/2015)... Inc., a worldwide provider of clinical research services headquartered in ... has set a new quarterly earnings record in Q3 of 2015.  ... Q3 of 2014 to Q3 of 2015.   ... the establishment of an Asia-Pacific office to ... and Mexico , with the establishment ...
(Date:11/24/2015)... Massachusetts , November 24, 2015 SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ... , Chief Financial Officer, will participate in the Piper Jaffray 27 ... , NY on Tuesday, December 1, 2015, at 8:30 a.m. ...
(Date:11/24/2015)... , Nov. 24, 2015  Twist Bioscience, ... that Emily Leproust, Ph.D., Twist Bioscience chief executive ... Healthcare Conference on December 1, 2015 at 3:10 ... in New York City. --> ... . Twist Bioscience is on Twitter. Sign ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW Telbec/ - ProMetic Life Sciences ... today that Mr. Pierre Laurin , President and Chief ... at the upcoming Piper Jaffray 27 th Annual Healthcare ... on December 1-2, 2015. st , at ... one-on-one meetings throughout the day. The presentation will be available ...
Breaking Biology Technology:
(Date:11/12/2015)... 11, 2015   Growing need for low-cost, ... has been paving the way for use of ... discrete analytes in clinical, agricultural, environmental, food and ... used in medical applications, however, their adoption is ... to continuous emphasis on improving product quality and ...
(Date:11/10/2015)... Nov. 10, 2015 About ... that helps to identify and verify the identity ... considered as the secure and accurate method of ... a particular individual because each individual,s signature is ... especially when dynamic signature of an individual is ...
(Date:11/4/2015)... --> --> ... Transparency Market Research "Home Security Solutions Market - Global Industry ... 2022", the global home security solutions market is expected to reach ... market is estimated to expand at a CAGR of ... Rising security needs among customers at homes, the emergence ...
Breaking Biology News(10 mins):